Developed within the University of Tours for a year and a half, the 100% French nasal vaccine took a further step this Thursday with the announcement of the creation of a start-up responsible for the development and operation of the solution.
A vaccine which will be produced this semester by the Toulouse company Bioways.

Pre-clinical tests carried out in the laboratory had already been able to check the effectiveness of the vaccine after two nasal immunizations spaced 3 weeks apart. These tests were also carried out on the Delta variant and confirmed their effectiveness.
And it is this element that will undoubtedly be the most decisive. Consisting of the Spike protein and viral proteins not subject to mutation, the nasal vaccine planned, according to the announcement made on Thursday, to counter the strain of Sras-CoV-2 currently circulating despite its numerous mutations.

According to this Thursday’s announcement, “subject to compliance with a tight schedule and sufficient external investment”, “this project can contribute to emerging from the pandemic crisis”.

The start-up created for the occasion, LoValTech, holds an exclusive worldwide operating license for the product. As such, a fundraiser has been announced.

In addition to being non-invasive, the advantage of this nasal vaccine lies in the early neutralization of the original virus and its variants, blocking any risk of contamination by a vaccinated individual.

However, the marketing is not for now. The transition to the clinical phase is now on track but the product will not be marketed before the end of 2023, beginning of 2024.